Current diagnostic and prognostic tumor biomarkers in use for the prevention and early detection of ovarian cancer are inadequate. Dr. Robin Farias-Eisner and colleagues have recently demonstrated that serum CA-125 levels, the most commonly utilized biomarker for clinical screening and prognosis in patients with ovarian cancer, do not predict the outcome of cytoreductive surgery in patients with advanced epithelial ovarian cancer. The creation of a panel of biomarker proteins for the early detection and predictive of clinical outcome for any type of cancer is a goal of many researchers and clinicians fighting the war against cancer.
Farias-Eisner's laboratory has published the first report identifying three ovarian cancer biomarker protein panels that, when used together, effectively distinguished serum samples from healthy controls and patients with either benign or malignant ovarian neoplasia. Furthermore, the researchers have now confirmed the identity of five of the fourteen proteins. They believe that a relationship may exist between HDL-associated proteins and ovarian cancer and that a disruption in the balance of these proteins may play an important role in the development and progression of ovarian cancer.
Selected Cancer-Related Publications:
Farias-Eisner R. Differential association of hemoglobin with pro-inflammatory high density lipoproteins in atherogenic/hyperlipidemic mice - a novel biomarker of atherosclerosis. J Biol Chem. 2007.
Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005; 5(17): 4589-96.
Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem. 2004; 279(30): 31735-44.
Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A. 2003; 100(21): 12343-8.
Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2003; 13(2): 120-4.